The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

If you believe in the Efficient Market hypothesis, you had a good week. Despite a hotter-than-expected CPI print, a rise in credit card delinquencies, and the Trump administration’s announcement of 25 ...

Here are 5 of CFRA analysts' top growth stocks that have reported at least 15% annual revenue growth in the past three years.

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread.

Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Most economists expect muted U.S. economic growth in the coming quarters, and some indicators suggest a mild U.S. recession is still a possibility. It may become difficult for investors to ...